IGF1 and neoplasm: When metformin decreases circulating levels of insulin and IGF1, it not only deactivates RAS/RAF/MAPK and PI3K/AKT/mTOR pathways, but also downregulates other tumor-stimulating molecules such as growth factors, sex hormones, proinflammatory cells, cytokines, and metabolic intermediates.